Brief: Elicio Therapeutics Presents Preclinical Data On Its Lymph Node-Targeted Sars-COV-2 Amphiphile Vaccine, Eli-005
06/07/2022 12:37
July 6 (Reuters) - Elicio Therapeutics Inc ELTX.O :
* ELICIO THERAPEUTICS PRESENTS PRECLINICAL DATA ON ITS LYMPH
NODE-TARGETED SARS-COV-2 AMPHIPHILE VACCINE, ELI-005, AT THE
2022 KEYSTONE SYMPOSIA ON VIRAL IMMUNITY: BASIC MECHANISMS AND
THERAPEUTIC APPLICATIONS
Source text for Eikon: ID:nGNX1fhCd6
Further company coverage: ELTX.O
Recent news on Elicio Therapeutics
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Elicio Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study (updated)